ClinicalTrials.gg
TerminatedNCT04633447THEIAUpdated Jul 1, 2025Results posted

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

A Phase 2 interventional study of Guselkumab and Placebo in Giant Cell Arteritis, sponsored by Janssen Research & Development, LLC. Terminated at 30 sites in 9 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study primary endpoint was not met

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Giant Cell Arteritis with a site in Italy — 1 open to participants now, 1 under way, none of them phase 3. Giant Cell Arteritis · Italy.

Enrollment
8th of 10
53 · median 77
Started
2020
the only one that year
Phase 2
2 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Janssen Research & Development, LLC

Among the 12 studies in Giant Cell Arteritis with a site in Italy, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2, and was the 9th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

1 of the 12 studies in Giant Cell Arteritis with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Giant Cell Arteritis with a site in Italy, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell arteritis (GCA).

Read the detailed description

Giant cell arteritis (GCA) is a non-necrotizing granulomatous systemic vasculitis of unknown etiology affecting medium-sized and large arteries usually accompanied or preceded by systemic inflammation. Guselkumab is a monoclonal antibody (mAb) that binds to the p19 sub-unit of human interleukin (IL)-23 with high affinity and blocks binding of extracellular IL-23 to cell surface IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent activation and cytokine production. It is used in treatment of psoriatic arthritis, generalized pustular psoriasis, erythrodermic psoriasis. The study consists of a screening period (less than or equal to [\<=] 6 weeks), double-blind treatment period (48 weeks), and safety follow-up period (12 weeks). Participants who complete the Week 52 visit and are assessed to be in glucocorticoid (GC)-free remission, may have the option to participate in the long-term extension (LTE) period of the study for up to 12 months. This study will evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of guselkumab in combination with a 26-week GC taper regimen for the treatment of active new-onset or relapsing GCA in adult participants. The total duration of the study is up to 66 weeks for the main study and for participants that continue in the LTE period, the total study duration will be up to 112 weeks.

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Giant cell arteritis (GCA) according to the revised American College of Rheumatology criteria
  • GCA diagnosis confirmed by either temporal artery revealing features of GCA either at time of diagnosis or at other timepoint during disease history; or evidence of cranial GCA either at time of diagnosis or at other timepoint during disease history by cranial doppler-ultrasound; or cranial Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography; or other imaging modality upon agreement with the sponsor or evidence of GCA by angiography or cross-sectional imaging (ultrasound, MRI, computed tomography [CT], positron emission tomography [PET])
  • Have new onset or relapsing GCA
  • Have active GCA within 6 weeks of first study intervention: Active GCA: presence of signs and symptoms of GCA and elevated erythrocyte sedimentation rate (ESR) greater than or equal to (>=) 30 millimeter per hour (mm/hour), or C-reactive protein (CRP) >= 10 milligrams per liter (mg/L) (or 1 milligrams per deciliter [mg/dL]), attributed to active GCA. ESR >= 30 mm/hour or CRP >= 10 mg/L (or 1 mg/dL) is not required if active GCA has been confirmed by a positive temporal artery biopsy or ultrasound or other imaging modality within 6 weeks of first study intervention
  • Clinically stable GCA disease on a (GC) dose between 20 and 60 milligrams per day (mg/day) (prednisone or equivalent) at randomization such that the participant is able to safely participate in the protocol defined prednisone taper regimen, in the opinion of the investigator

Exclusion criteria

Exclusion criteria

  • Has any known severe or uncontrolled GCA complications
  • Has any rheumatic disease other than GCA such that could interfere with assessment of GCA
  • Has a current diagnosis or signs or symptoms of severe, progressive, or concomitant medical condition that places the participant at risk by participating in this study)
  • Has or has had any major ischemic event, within 12 weeks of first study intervention. Has a personal history of arterial thrombosis or venous thromboembolism (including deep venous thrombosis [DVT] and Pulmonary Embolism [PE])
  • Has any comorbidities requiring 3 or more courses of systemic GCs within 12 months of first study intervention, AND, inability, in the opinion of the investigator, to withdraw GC therapy through protocol-defined taper regimen due to suspected or established adrenal insufficiency, OR, currently on systemic chronic GC therapy for reasons other than GCA and be GC dependent and have the potential to flare due to GC tapering (e.g. unstable asthma, unstable )
  • Has a history of, or ongoing, chronic or recurrent infectious disease
  • Has received within specified timeframe, or 5 half-lives (whichever is greater) , or has failed treatment with any or approved biologic agents or Janus Kinase Inhibitor prior to first study intervention
  • Use of any of the following systemic treatments within the specified timeframe prior to study start: Any cytotoxic agents (cyclophosphamide, chlorambucil, nitrogen mustard, or other alkylating agents) with 6 months; Hydroxychloroquine, cyclosporine A, azathioprine, tacrolimus, sirolimus, sulfasalazine, leflunomide with cholestyramine washout or mycophenolate mofetil/mycophenolic acid within 3 months; Intramuscular, intra-articular, intrabursal, epidural, intra-lesional or IV GCs within 6 week; and Methotrexate (MTX) within 12 weeks. If started MTX >12 weeks prior to first study intervention MTX must have been at a stable dose for minimally 4 weeks and must not be receiving more than 25 mg oral or SC MTX per week
  • Has chronic continuous use of systemic GCs for greater than (>) 4 years or inability, in the opinion of the investigator, to withdraw GC treatment through protocol-defined taper regimen due to suspected or established adrenal insufficiency
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Guselkumab

    Participants will receive guselkumab subcutaneously (SC) every 4 weeks from Week 0 through Wweek 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.

    Drug: Guselkumab

  • Experimental
    Placebo

    Participants will receive matching placebo SC every 4 weeks from Week 0 through Week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections every 4 weeks starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.

    Drug: Placebo

Interventions

  • Guselkumab will be administered subcutaneously.

    Also known as: Tremfya, CNTO 1959

  • DrugPlacebo

    Matching placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Main Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 28

    GC free remission at Week 28 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Week 28; (2) absence of GCA flare from first dose of the study drug through Week 28; and (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Week 28

Secondary outcomes

  1. Main Study: Percentage of Participants Achieving GC-Free Remission at Weeks 28, 32, 36, 40, 44, 48 and 52

    GC free remission was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52

  2. Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Erythrocyte Sedimentation Rate (ESR) at Weeks 28, 32, 36, 40, 44, 48 and 52

    GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR was defined as ESR less than (\<) 30 millimeter per hour (mm/hr) at Weeks 28, 32, 36, 40, 44, 48 and 52. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52

  3. Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of C-Reactive Protein (CRP) at Weeks 28, 32, 36, 40, 44, 48 and 52

    GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of CRP is defined as CRP \<10 milligrams per liter (mg/L) or \<1 milligrams per deciliter (mg/dL). GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52

  4. Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Both ESR and CRP at Weeks 28, 32, 36, 40, 44, 48 and 52

    GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR is defined as ESR \< 30 mm/hr at Weeks 28, 32, 36, 40, 44, 48 and 52. Normalization of CRP is defined as CRP \<10 mg/L or \<1 mg/dL. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Weeks 28, 32, 36, 40, 44, 48 and 52

  5. Main Study: Cumulative Glucocorticoid (GC) Dose

    Total cumulative GC dose administered included GCA taper, GC rescue therapy as well as for all other indications (any oral GC) from baseline (Day 1) up to Weeks 28 and 52 was reported.

    Time frame: Baseline (Day 1) up to Weeks 28 and 52

  6. Main Study: Time to First GCA Disease Flare or Discontinuation of Study Intervention Due to Adverse Event (AE) of Worsening of GCA

    Time to occurrence of GCA disease flare was defined as the time from first dose of the study agent to the occurrence of the first observation of GCA disease flare or discontinuation due to adverse event (AE) of worsening of GCA. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Baseline (Day 1) up to Week 30 and Week 52

  7. Main Study: Number of Participants With GCA Disease Flares or Discontinuation of Study Intervention Due to AE of Worsening of GCA

    Number of participants with GCA disease flares or discontinuation of study intervention due to AE of worsening of GCA were reported. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

    Time frame: Baseline (Day 1) up to Week 30 and Week 52

  8. Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs (including serious and non-serious AEs) were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

    Time frame: Baseline (Day 1) up to Week 60

  9. Number of Participants With TEAEs by System Organ Class (SOC) With a Frequency Threshold of 5 Percent (%) or More

    Number of participants with TEAEs (including serious and non-serious AEs) by SOC with a frequency threshold of 5 percent (%) or more were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

    Time frame: Baseline (Day 1) up to Week 60

  10. Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs)

    Number of participants with treatment emergent SAEs were reported. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

    Time frame: Baseline (Day 1) up to Week 60

  11. Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significant abnormal vital signs criteria: Pulse rate: \<50 beats per minutes (bpm) and with greater than (\>) 20 bpm decrease from baseline, \>115 bpm and with \>30 bpm increase from baseline; Systolic blood pressure (SBP): \<90 millimeters of mercury \[mmHg\] and with \>30 mmHg decrease from baseline, \>150 mmHg and with \>40 mmHg increase from baseline; Diastolic blood pressure (DBP): \<50 mmHg and with \>20 mmHg decrease from baseline, \>95 mmHg and with \>30 mmHg increase from baseline; Interarm blood pressure: Interarm blood pressure difference greater than or equal to (\>=) 15 mmHg in systolic blood pressure at 3 consecutive visits; Temperature (Temp): \>38.4 Degree Celsius (C) and with \>=1 C increase from baseline; Weight (kilogram \[kg\]): decrease 10 percent (%) from baseline, increase 10% from baseline; Respiratory Rate: \>20 breaths per minute.

    Time frame: Baseline (Day 1) up to Week 60

  12. Main Study: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Number of participants with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or 4 abnormalities in clinical laboratory tests: hematology and chemistry were reported. Clinical laboratory abnormalities of living participants were assessed as per NCI CTCAE version 5, grades (0-4), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. As per the discretion of investigator, laboratory abnormalities with NCI CTCAE Grade 3 or 4 were considered clinically significant. Combined data of Grade 3 and 4 abnormalities are reported as planned. Only those categories in which at least 1 participant had data were reported.

    Time frame: Baseline (Day 1) up to Week 60

  13. Main Study: Serum Concentrations of Guselkumab

    Serum concentrations of Guselkumab over time was reported.

    Time frame: Pre-dose and 1 hour post dose on Week 0 (Day 1), Week 4 (Day 28), and Week 8 (Day 56); Week 12 (Day 84), Week 16 (Day 112), Week 28 (Day 196), Week 52 (Day 364)

  14. Main Study: Number of Participants With Antibodies to Guselkumab

    Number of participants with antibodies to Guselkumab were reported.

    Time frame: Baseline (Day 1) up to Week 28, Week 52

07

Results

Posted Jul 1, 2025

Participant flow

Main Study (From Week 0 up to Week 60)
Participant flow — Main Study (From Week 0 up to Week 60)
MilestoneGuselkumabPlacebo
Started3518
Participants enrolled post pa-5 who received placebo matching to guselkumab 200 mg from week 0011
Participants enrolled post pa-5 who received guselkumab 200 mg from week 0190
Completed2212
Not completed136
Withdrew: Adverse event82
Withdrew: Study terminated by sponsor33
Withdrew: Physician decision01
Withdrew: Withdrawal by subject20
LTE Period (Week 52 up to Week 112)
Participant flow — LTE Period (Week 52 up to Week 112)
MilestoneGuselkumabPlacebo
Started96
Completed53
Not completed43
Withdrew: Study terminated by sponsor32
Withdrew: Adverse event11

Outcome measures

PrimaryMain Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 28

GC free remission at Week 28 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Week 28; (2) absence of GCA flare from first dose of the study drug through Week 28; and (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Week 28
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 28
Percentage of ParticipantsMain Study: GuselkumabMain Study: Placebo
Main Study: Percentage of Participants Achieving Glucocorticoid (GC)-Free Remission at Week 2840.033.3
Statistical analysis
  • Main Study: Guselkumab vs Main Study: Placebo · Cochran-Mantel-Haenszel · p = =0.638 · Difference in percentage: 6.6 · 90% CI -14.7 to 27.9
SecondaryMain Study: Percentage of Participants Achieving GC-Free Remission at Weeks 28, 32, 36, 40, 44, 48 and 52

GC free remission was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving GC-Free Remission at Weeks 28, 32, 36, 40, 44, 48 and 52
Percentage of ParticipantsMain Study: GuselkumabMain Study: Placebo
At Week 2840.033.3
At Week 3234.333.3
At Week 3634.333.3
At Week 4034.333.3
At Week 4434.333.3
At Week 4831.427.8
At Week 5225.727.8
SecondaryMain Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Erythrocyte Sedimentation Rate (ESR) at Weeks 28, 32, 36, 40, 44, 48 and 52

GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR was defined as ESR less than (\<) 30 millimeter per hour (mm/hr) at Weeks 28, 32, 36, 40, 44, 48 and 52. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Erythrocyte Sedimentation Rate (ESR) at Weeks 28, 32, 36, 40, 44, 48 and 52
Percentage of ParticipantsMain Study: GuselkumabMain Study: Placebo
At Week 2822.95.6
At Week 3222.911.1
At Week 3622.916.7
At Week 4025.716.7
At Week 4422.911.1
At Week 4820.022.2
At Week 5222.916.7
SecondaryMain Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of C-Reactive Protein (CRP) at Weeks 28, 32, 36, 40, 44, 48 and 52

GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active Giant cell arteritis (GCA) at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52 (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of CRP is defined as CRP \<10 milligrams per liter (mg/L) or \<1 milligrams per deciliter (mg/dL). GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of C-Reactive Protein (CRP) at Weeks 28, 32, 36, 40, 44, 48 and 52
Percentage of ParticipantsMain Study: GuselkumabMain Study: Placebo
At Week 2822.916.7
At Week 3220.016.7
At Week 3625.722.2
At Week 4028.633.3
At Week 4425.727.8
At Week 4820.027.8
At Week 5217.122.2
SecondaryMain Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Both ESR and CRP at Weeks 28, 32, 36, 40, 44, 48 and 52

GC-free remission at Weeks 28, 32, 36, 40, 44, 48 and 52 was defined as (1) no signs or symptoms of active GCA at Weeks 28, 32, 36, 40, 44, 48 and 52 respectively; (2) absence of GCA flare from first dose of the study drug through Weeks 28, 32, 36, 40, 44, 48 and 52; (3) adherence to the protocol specified 26-week GC taper regimen. Normalization of ESR is defined as ESR \< 30 mm/hr at Weeks 28, 32, 36, 40, 44, 48 and 52. Normalization of CRP is defined as CRP \<10 mg/L or \<1 mg/dL. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · Percentage of Participants
Main Study: Percentage of Participants Achieving Both GC-Free Remission and Normalization of Both ESR and CRP at Weeks 28, 32, 36, 40, 44, 48 and 52
Percentage of ParticipantsMain Study: GuselkumabMain Study: Placebo
At Week 2814.35.6
At Week 3217.111.1
At Week 3620.016.7
At Week 4022.916.7
At Week 4417.111.1
At Week 4814.322.2
At Week 5217.116.7
SecondaryMain Study: Cumulative Glucocorticoid (GC) Dose

Total cumulative GC dose administered included GCA taper, GC rescue therapy as well as for all other indications (any oral GC) from baseline (Day 1) up to Weeks 28 and 52 was reported.

Time frame:
Baseline (Day 1) up to Weeks 28 and 52
Reported as:
Median · Milligrams (mg)
Main Study: Cumulative Glucocorticoid (GC) Dose
Milligrams (mg)Main Study: GuselkumabMain Study: Placebo
Baseline (Day 1) up to Week 282231.0 (1315 to 4146)2205.0 (1736 to 6010)
Baseline (Day 1) up to Week 522418.5 (1315 to 4319)2902.1 (1736 to 7345)
SecondaryMain Study: Time to First GCA Disease Flare or Discontinuation of Study Intervention Due to Adverse Event (AE) of Worsening of GCA

Time to occurrence of GCA disease flare was defined as the time from first dose of the study agent to the occurrence of the first observation of GCA disease flare or discontinuation due to adverse event (AE) of worsening of GCA. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Baseline (Day 1) up to Week 30 and Week 52
Reported as:
Median · Weeks
Main Study: Time to First GCA Disease Flare or Discontinuation of Study Intervention Due to Adverse Event (AE) of Worsening of GCA
WeeksMain Study: GuselkumabMain Study: Placebo
Baseline (Day 1) up to Week 30NA (27.71 to NA)29.71 (20.14 to NA)
Baseline (Day 1) up to Week 52NA (27.71 to NA)30.07 (20.14 to NA)
SecondaryMain Study: Number of Participants With GCA Disease Flares or Discontinuation of Study Intervention Due to AE of Worsening of GCA

Number of participants with GCA disease flares or discontinuation of study intervention due to AE of worsening of GCA were reported. GCA flare was defined as the recurrence of signs and symptoms of active GCA, with or without elevation of inflammatory markers, and with the necessity for an increase in GC dose for GCA.

Time frame:
Baseline (Day 1) up to Week 30 and Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With GCA Disease Flares or Discontinuation of Study Intervention Due to AE of Worsening of GCA
ParticipantsMain Study: GuselkumabMain Study: Placebo
Baseline up to Week 30: 1 Flare108
Baseline up to Week 30: 2 Flares00
Baseline up to Week 30: >=3 Flares00
Baseline up to Week 52: 1 Flare137
Baseline up to Week 52: 2 Flares33
Baseline up to Week 52: >=3 Flares00
SecondaryMain Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs (including serious and non-serious AEs) were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

Time frame:
Baseline (Day 1) up to Week 60
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsMain Study: GuselkumabMain Study: Placebo
Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)3417
SecondaryNumber of Participants With TEAEs by System Organ Class (SOC) With a Frequency Threshold of 5 Percent (%) or More

Number of participants with TEAEs (including serious and non-serious AEs) by SOC with a frequency threshold of 5 percent (%) or more were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

Time frame:
Baseline (Day 1) up to Week 60
Reported as:
Count of participants · Participants
Number of Participants With TEAEs by System Organ Class (SOC) With a Frequency Threshold of 5 Percent (%) or More
ParticipantsMain Study: GuselkumabMain Study: Placebo
Infections and infestations2111
Musculoskeletal and connective tissue disorders195
Vascular disorders1811
Gastrointestinal disorders102
General disorders and administration site conditions106
Nervous system disorders99
Eye disorders83
Respiratory, thoracic and mediastinal disorders84
Skin and subcutaneous tissue disorders81
Injury, poisoning and procedural complications72
Investigations60
Endocrine disorders50
Psychiatric disorders41
Metabolism and nutrition disorders31
Neoplasms benign, malignant and unspecified (incl cysts and polyps)31
Cardiac disorders22
Renal and urinary disorders21
Reproductive system and breast disorders11
SecondaryMain Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs)

Number of participants with treatment emergent SAEs were reported. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE occurred at or after the initial administration of study intervention through the end of the main study was considered to be treatment emergent.

Time frame:
Baseline (Day 1) up to Week 60
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs)
ParticipantsMain Study: GuselkumabMain Study: Placebo
Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs)60
SecondaryMain Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs

Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significant abnormal vital signs criteria: Pulse rate: \<50 beats per minutes (bpm) and with greater than (\>) 20 bpm decrease from baseline, \>115 bpm and with \>30 bpm increase from baseline; Systolic blood pressure (SBP): \<90 millimeters of mercury \[mmHg\] and with \>30 mmHg decrease from baseline, \>150 mmHg and with \>40 mmHg increase from baseline; Diastolic blood pressure (DBP): \<50 mmHg and with \>20 mmHg decrease from baseline, \>95 mmHg and with \>30 mmHg increase from baseline; Interarm blood pressure: Interarm blood pressure difference greater than or equal to (\>=) 15 mmHg in systolic blood pressure at 3 consecutive visits; Temperature (Temp): \>38.4 Degree Celsius (C) and with \>=1 C increase from baseline; Weight (kilogram \[kg\]): decrease 10 percent (%) from baseline, increase 10% from baseline; Respiratory Rate: \>20 breaths per minute.

Time frame:
Baseline (Day 1) up to Week 60
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsMain Study: GuselkumabMain Study: Placebo
Pulse rate: <50 bpm and with >20 bpm decrease10
Pulse rate: >115 bpm and with >30 bpm increase00
Systolic BP: <90 mmHg and >30 mmHg decrease20
Systolic BP: >150 mmHg and >40 mmHg increase02
Diastolic BP: <50 mmHg and >20 mmHg decrease20
Diastolic BP: >95 mmHg and >30 mmHg increase11
Interarm BP:BP difference >=15 mmHg in systolic BP22
Temp: >38.4 C and >=1 C increase from baseline00
Weight: Decrease 10% from baseline01
Weight: Increase 10% from baseline62
Respiratory Rate: >20 breaths per minute14
SecondaryMain Study: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Number of participants with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 3 or 4 abnormalities in clinical laboratory tests: hematology and chemistry were reported. Clinical laboratory abnormalities of living participants were assessed as per NCI CTCAE version 5, grades (0-4), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. As per the discretion of investigator, laboratory abnormalities with NCI CTCAE Grade 3 or 4 were considered clinically significant. Combined data of Grade 3 and 4 abnormalities are reported as planned. Only those categories in which at least 1 participant had data were reported.

Time frame:
Baseline (Day 1) up to Week 60
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsMain Study: GuselkumabMain Study: Placebo
Chemistry: Creatinine Increased10
Chemistry: Alanine Aminotransferase Increased10
Hematology: Lymphocyte Count Decreased33
SecondaryMain Study: Serum Concentrations of Guselkumab

Serum concentrations of Guselkumab over time was reported.

Time frame:
Pre-dose and 1 hour post dose on Week 0 (Day 1), Week 4 (Day 28), and Week 8 (Day 56); Week 12 (Day 84), Week 16 (Day 112), Week 28 (Day 196), Week 52 (Day 364)
Reported as:
Mean · Microgram per milliliter (mcg/mL
Main Study: Serum Concentrations of Guselkumab
Microgram per milliliter (mcg/mLMain Study: Guselkumab
Pre dose on Week 0 (Day 1)0.00 ± 0.000
1 Hour Post Dose on Week 0 (Day 1)130.93 ± 45.522
Pre dose on Week 4 (Day 28)11.21 ± 6.616
1 Hour Post Dose on Week 4 (Day 28)150.21 ± 34.952
Pre dose on Week 8 (Day 56)19.71 ± 23.002
1 Hour Post Dose on Week 8 (Day 56)127.14 ± 68.157
Week 12 (Day 84)19.16 ± 17.831
Week 16 (Day 112)15.81 ± 9.644
Week 28 (Day 196)12.63 ± 4.824
Week 52 (Day 364)12.55 ± 4.701
SecondaryMain Study: Number of Participants With Antibodies to Guselkumab

Number of participants with antibodies to Guselkumab were reported.

Time frame:
Baseline (Day 1) up to Week 28, Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Antibodies to Guselkumab
ParticipantsMain Study: Guselkumab
Baseline (Day 1) up to Week 281
Baseline (Day 1) up to Week 523

Adverse events

Collected over Main study: All-Cause Mortality: From Screening (-6 weeks) up to Week 60; SAEs & Other AEs: Baseline (Day 1) up to Week 60. LTE Period: From Week 52 (LTE Week 0) up to Week 112 (LTE Week 60). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Guselkumab1/35 (2.9%)6/35 (17.1%)31/35 (88.6%)
Main Study: Placebo0/18 (0%)0/18 (0%)17/18 (94.4%)
LTE Period: Guselkumab0/9 (0%)0/9 (0%)6/9 (66.7%)
LTE Period: Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventMain Study: GuselkumabMain Study: PlaceboLTE Period: GuselkumabLTE Period: Placebo
Abdominal SepsisInfections and infestations1/350/180/90/6
UrosepsisInfections and infestations1/350/180/90/6
Fractured SacrumInjury, poisoning and procedural complications1/350/180/90/6
Alanine Aminotransferase IncreasedInvestigations1/350/180/90/6
Aspartate Aminotransferase IncreasedInvestigations1/350/180/90/6
Acute Kidney InjuryRenal and urinary disorders1/350/180/90/6
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/350/180/90/6
Peripheral Artery StenosisVascular disorders1/350/180/90/6
Most frequent other events
Showing 10 of 95
Most frequent other events
EventMain Study: GuselkumabMain Study: PlaceboLTE Period: GuselkumabLTE Period: Placebo
Giant Cell ArteritisVascular disorders17/3510/180/91/6
HeadacheNervous system disorders6/357/180/90/6
Upper Respiratory Tract InfectionInfections and infestations4/351/182/92/6
Covid-19Infections and infestations8/355/180/90/6
ArthralgiaMusculoskeletal and connective tissue disorders6/350/181/91/6
Tinea PedisInfections and infestations0/350/180/91/6
FallInjury, poisoning and procedural complications2/351/180/91/6
DyslipidaemiaMetabolism and nutrition disorders0/350/180/91/6
OsteoporosisMusculoskeletal and connective tissue disorders0/351/180/91/6
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/351/180/91/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GuselkumabPlaceboTotal
<=18 years000
Between 18 and 65 years639
>=65 years291544
Age, Continuous
Age, Continuous(years)GuselkumabPlaceboTotal
Mean71.9 ± 7.6570.8 ± 7.1471.5 ± 7.43
Sex: Female, Male
Sex: Female, Male(Participants)GuselkumabPlaceboTotal
Female251237
Male10616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GuselkumabPlaceboTotal
Hispanic or Latino8311
Not Hispanic or Latino271542
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GuselkumabPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White351853
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)GuselkumabPlaceboTotal
Belgium404
Canada8412
France303
Germany235
Israel314
Italy5510
Poland202
Spain8513
08

Study locations

30 sites
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Mount Sinai Hospital
    Toronto, Ontario M5T 3L9, Canada
  • Hopital du Sacre-Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
  • CHU Dijon
    Dijon, 21000, France
  • Hopital Cochin
    Paris, 75014, France
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • medius KLINIK KIRCHHEIM
    Kirchheim unter Teck, 73230, Germany
  • Universitatsklinik Tubingen
    Tübingen, 72076, Germany
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, 49100, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azianeda Ospedaliera dell'alto adige - Ospedale di Brunico
    Bolzano, 39100, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35121, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Azienda USL 4 Prato
    Prato, 59100, Italy
  • ASUI Santa Maria della Misericordia di Udine
    Udine, 33100, Italy
  • Szpital Uniwersytecki Nr 2 w Bydgoszczy
    Bydgoszcz, 85 168, Poland
  • Szpital Specjalistyczny im. J. Dietla
    Krakow, 31-121, Poland
  • NZOZ Lecznica MAK MED S C
    Nadarzyn, 05 830, Poland
  • Hosp Univ A Coruna
    A Coruña, 15006, Spain
  • Hosp Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hosp. Clinico San Carlos
    Madrid, 28040, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp Regional Univ de Malaga
    Málaga, 29009, Spain
  • Hosp. Univ. Marques de Valdecilla
    Santander, 39008, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in May 2024, 41 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 18, 2020
StartActual
Dec 10, 2020
Primary completionActual
May 22, 2024
CompletionActual
May 22, 2024
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04633447
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Dec 10, 2020
Primary completion
May 22, 2024
Completion
May 22, 2024
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion